Precigen, Inc. PGEN
Precigen, Inc. (Nasdaq: PGEN) is a respiratory drug developer. Its lead program, Papzimeos (zopapogene imadenovec-drba; PRGN-2012), is in Phase 2 for recurrent respiratory papillomatosis (adults). Its next catalyst on record is Papzimeos: EMA review of Marketing Authorization Application (validated, under review) (date not stated).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Papzimeos — EMA review of Marketing Authorization Application (validated, under review) (date not stated). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Papzimeos (zopapogene imadenovec-drba) | adult recurrent respiratory papillomatosis (FDA full approval Aug 2025; EMA MAA under review; open-label retreatment trial ongoing; pediatric trial planned) | gene therapy | Approved |
| PRGN-2009 | HPV-associated oropharyngeal cancer (two NCI-CRADA Phase 2 trials) and recurrent/metastatic cervical cancer (Phase 2, with pembrolizumab) | vaccine | Phase 2 |
| PRGN-3006 (UltraCAR-T, CD33) | r/r AML and high-risk MDS (Phase 1/1b; enrollment complete) | cell therapy | Phase 1 |
| PRGN-3005 (UltraCAR-T, MUC16) | platinum-resistant ovarian/fallopian/peritoneal cancer (Phase 1/1b; enrollment paused) | cell therapy | Phase 1 |
| PRGN-3007 (UltraCAR-T, ROR1) | ROR1+ hematologic and solid tumors (Phase 1/1b; enrollment paused) | cell therapy | Phase 1 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 respiratory companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.